Definitive Healthcare Corp. Stock Price, News & Analysis

Definitive Healthcare (Nasdaq: DH) has launched its Atlas Dataset on Snowflake Marketplace, enabling joint customers to integrate healthcare commercial intelligence into their workflows. This integration allows for improved decision-making regarding commercialization efforts. Key datasets available include:

• NRx & TRx: Prescribing Activity - Offers insights into prescription activity and physician performance.
• Atlas US Healthcare Reference & Affiliations Dataset - Provides contact info, financials, and organizational data.
• RxDecision Insights - Focuses on optimizing sales force allocation and understanding treatment decisions.

Both companies aim to enhance market understanding and drive new revenue opportunities through data integration.

Definitive Healthcare (Nasdaq: DH) has launched DefinitiveConnect on Salesforce AppExchange, allowing customers to access healthcare data directly within Salesforce. This integration enables users to import over 300 data elements into Salesforce Account, Contact, or Lead records, providing valuable insights on facility metrics and organizational news. CEO Robert Musslewhite emphasized that DefinitiveConnect streamlines access to healthcare data, enhancing decision-making for commercial strategies. The launch is expected to accelerate business transformation and growth opportunities for customers, as noted by David Lee from AppExchange. Definitive Healthcare specializes in delivering commercial intelligence solutions for the healthcare sector.

Definitive Healthcare Corp. (Nasdaq: DH) announced that its Chief Financial Officer, Rick Booth, will present at the Raymond James 2023 Institutional Investors Conference on March 7, 2023, at 2:50 p.m. Eastern Time. Investors can access a live webcast of the presentation on the Definitive Healthcare investor relations website. A replay will also be available for a limited time.

Definitive Healthcare is a leader in healthcare commercial intelligence, transforming data and analytics to help clients identify market opportunities. To learn more, visit definitivehc.com.

Definitive Healthcare reported a strong performance for Q4 and full year 2022, with revenue growth of 31% to $60.6 million in Q4, and a 34% increase to $222.7 million for the year. GAAP net income improved to $6.7 million, contrasting with a loss of $14.8 million in Q4 2021. Adjusted net income also rose to $10.5 million. For 2023, the company anticipates revenue between $249.0 million and $255.0 million, reflecting a 14% year-over-year increase. The launch of the Atlas Dataset and several key customer contracts signify substantial growth potential in the healthcare intelligence market.

GovForce, a technology company focused on government contractors, has secured $2.5 million in seed equity funding led by QED Investors and Humba Ventures. This funding aims to enhance its software platform designed to assist prime contractors with performance monitoring and compliance management. With government contractors managing approximately $700 billion annually in federal contracts, effective compliance is crucial. The GovForce platform addresses heightened security and reporting challenges in the industry, streamlining processes for subcontractor management, ultimately improving efficiency and performance.

Definitive Healthcare (Nasdaq: DH) announced it will release its fourth quarter and full year financial results on February 23, 2023, after market close. The company will hold a conference call at 5:00 PM ET to discuss the results. Investors can listen to the event via a live audio webcast on the Definitive Healthcare Investor Relations website. The replay of the call will be available until March 9, 2023, for those who cannot attend the live session.

Definitive Healthcare specializes in healthcare commercial intelligence, aiding clients in identifying market opportunities.

Definitive Healthcare (Nasdaq: DH) announced the launch of its Atlas Dataset, a comprehensive resource for healthcare commercial intelligence. This dataset integrates information on over 15 million healthcare professionals and 300,000 organizations, positioning it as a leading tool for clients to make informed decisions. An independent survey indicated the dataset's top ranking for reference and affiliation data. It includes key components such as Atlas Reference & Affiliation, All-Payor Claims, and Prescription Claims, enhancing visibility into healthcare operations and contributing to improved market understanding.

Definitive Healthcare (Nasdaq: DH) reported a 60% increase in its Atlas Prescription Claims and significant growth in Atlas All-Payor Claims. This expansion enhances data for healthcare providers to improve patient outcomes, particularly in areas like rare diseases and oncology, with nearly 20% increases in these sectors. CEO Robert Musslewhite emphasized the value of the expanded dataset for driving commercial success, refining methodologies, and increasing patient cohort accuracy. The updated Atlas Dataset equips clients with comprehensive insights into patient care, provider behavior, and market trends.

Definitive Healthcare Corp. (Nasdaq: DH) announced its participation in the 25th Annual Needham Growth Conference. CEO Robert Musslewhite and CFO Rick Booth will present on January 11, 2023, at 11:00 a.m. ET. Interested parties can access the live webcast via the Definitive Healthcare investor relations website.

The company is recognized for its healthcare commercial intelligence, using data and analytics to assist clients in navigating market opportunities effectively.